All In Biotech

Drug Trial Radar · NCT05267899

A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors

A Phase I, First in Human, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301, a Lipid Nanoparticle Suspension of Akt-1 Antisense Oligonucleotide, in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

24

Planned (sponsor's estimate)

Start

Aug 1, 2022

Primary completion

Oct 15, 2024

Study completion Dec 31, 2024

Sponsor

Sponsor type
Industry
First posted
Mar 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the effects of a study medicine, WGI-0301 to find the best dose for treating solid tumors, and to see how safe and tolerable the study drug is for patients with solid tumors. The study is also done to learn how the study drug is taken up by your body; this is called Pharmacokinetic (PK) studies and how the study drug affects the body; this is called Pharmacodynamics (PD)

Conditions

  • Advanced Solid Tumors

Interventions

  • WGI-0301Drug

    WGI-0301 is a lipid nanoparticle preparation of Archexin® for the treatment of advanced solid tumors.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerabilityTime frame: Approximately 16 months
  2. Recommended Phase 2 Dose of WGI-0301Time frame: Approximately 16 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Valkyrie Clinical Trials

    Los Angeles, California · Recruiting

  • The Oncology Institute of Hope and Innovation

    Whittier, California · Recruiting

  • University of Maryland, Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.